Here are five companies in which GV has chosen to invest, according to Becker’s coverage since Aug. 23:
- GV joined in with Pittsburgh-based UPMC Enterprises to participate in a $51 million series B financing round for drug discovery company Cerevance.
- The venture capital arm invested $28.1 million in mental health startup Firsthand.
- GV joined with Boston-based Mass General Brigham to participate in the $32 million seed funding round for Rippl, a digital mental health company focusing on older adults.
- GV took part in a $72.5 million series A financing round for Pretzel Therapeutics, a company that uses mitochondrial biology to treat disease.
- GV participated in a $65 million series A financing round for precision medicine startup Vicinitas Therapeutics.
